Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Coliswel
Coliswel (Colistimethate Injection) is a last-resort antibiotic used in the management of life-threatening infections caused by multidrug-resistant Gram-negative bacteria. It is particularly effective in patients with hospital-acquired pneumonia, bloodstream infections, and complicated UTIs where conventional antibiotics fail. Coliswel is available in an injectable form for intravenous or intramuscular administration, ensuring rapid and targeted antibacterial action.
Uses of Coliswel
Treatment of Multidrug-Resistant (MDR) Gram-negative Infections
Nosocomial Pneumonia, including Ventilator-Associated Pneumonia (VAP)
Bacteremia and Septicemia
Complicated Urinary Tract Infections (UTIs)
Severe Infections Due to Pseudomonas aeruginosa & Acinetobacter baumannii
Benefits of Coliswel
Highly Effective Against MDR Gram-Negative Pathogens
Essential for Treating Hospital-Acquired and Ventilator-Associated Infections
Rapid Bactericidal Action, Reducing Mortality in Severe Cases
Can Be Used in Combination Therapy for Better Clinical Outcomes
Available in Injectable Form for Immediate Systemic Effect
Mechanism of Action of Coliswel
Colistimethate sodium acts by binding to lipopolysaccharides and phospholipids in the bacterial outer membrane, disrupting its integrity and leading to cell lysis and bacterial death. Its concentration-dependent bactericidal activity makes it effective against drug-resistant Gram-negative bacteria, including carbapenem-resistant strains.